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Figure 1. Participant flow diagram. 
 
Figure 2. Adjusted Cox proportional hazard ratios (log-linear) of an event, all-cause mortality, 
and cardiovascular mortality in CPRD patients on DOACs (reference 160mmHg, 140mmHg 
and 120mmHg).  
Adjusted for sex, age, stroke/ischemic heart disease, dementia, liver disease, and current 
alcohol use. Events include first stroke, recurrent stroke, myocardial infarction, symptomatic 
intracranial bleed, and significant gastrointestinal bleed.  
 
Figure 3. Adjusted Cox proportional hazard ratios (restricted cubic splines) of an event, all-
cause mortality, and cardiovascular mortality in CPRD patients on DOACs (reference 
160mmHg, 140mmHg and 120mmHg).  
Adjusted for sex, age, stroke/ischemic heart disease, dementia, liver disease, and current 
alcohol use. Events include first stroke, recurrent stroke, myocardial infarction, symptomatic 
intracranial bleed, and significant gastrointestinal bleed.  
 
Table 1: Cohort characteristics by post-DOACs initiation systolic blood pressure groups in 
CPRD patients on DOACs. 
 
Table 2: Incidence rate for an event, and all-cause and cardiovascular mortality by post-
DOACs initiation systolic blood pressure groups in CPRD patients on DOACs. 
 





Objective: Limited data exist to inform blood pressure (BP) thresholds for patients with atrial 
fibrillation (AF) prescribed direct oral anticoagulants (DOAC) therapy in the real world setting. 
Methods: Systolic blood pressure was measured in 9,051 primary care patients in England on 
DOACs for AF with post-initiation BP levels available within the Clinical Practice Research 
Datalink (CPRD). The incidence rate for the primary outcome of the first recorded event 
(defined as a diagnosis of first stroke, recurrent stroke, myocardial infarction, symptomatic 
intracranial bleed or significant gastrointestinal bleed) and of secondary outcomes all-cause 
mortality and cardiovascular mortality were calculated by post-initiation BP groups.  
Results: The Cox proportional hazard ratio (HR) of an event (crude and adjusted HR 1.04 [95% 
CI 1.00-1.08], p=0.077 and 0.071, respectively) did not differ significantly with a 10mmHg 
increase in systolic BP. The hazard of all-cause mortality (crude HR 0.83 [95% CI 0.80-0.86], 
p=0.000; adjusted HR 0.84 [95% CI 0.81-0.87], p=0.000) and cardiovascular mortality (crude 
HR 0.92 [95% CI 0.85-0.99], p=0.021; adjusted HR 0.93 [95% CI 0.86-1.00], p=0.041) 
demonstrated a significant inverse relationship with a 10mmHg increase in systolic BP. 
Patients with a systolic BP within 161-210mmHg had the lowest all-cause death rate, while 
patients with systolic BP within 121-140mmHg had the lowest cardiovascular death rate.  
 
Conclusion: Systolic BP values below 161mmHg are associated higher all-cause mortality, but 
lower event risk in patients with AF on DOAC therapy. This demonstrates a need for a 




Increasing systemic blood pressure (BP) levels are associated with a linear increase in 
cardiovascular complications such as heart failure, atrial fibrillation (AF), myocardial 
infarction, stroke and death [1]. Furthermore, AF is considered the most prevalent co-morbidity 
in people with hypertension [2]. In recent years several randomized controlled trials (RCTs) 
have provided data on the non-inferiority of direct oral anticoagulant therapy (DOACs) 
compared to an established anticoagulation strategy with warfarin for prevention of stroke or 
systemic embolism, often with preferential side effect profiles to match [3-6]. These include a 
consistently lower intracranial hemorrhage rate, and a comparable gastrointestinal hemorrhage 
rate for some DOACs in comparison with standard dose-adjusted Warfarin. However, BP 
threshold values pertaining to an increased risk of symptomatic intracranial hemorrhage are 
not available from the DOACs studies. Furthermore, data comparing systolic BP at baseline 
between clinical trial populations (e.g. Apixaban and Warfarin) demonstrated SBP values of 
130mmHg (25th percentile of 120mmHg and 75th percentile of 140mmHg) in both groups and 
no overall effect on bleeding risk, arguably as might be expected at these levels in a trial 
population [7]. Therefore, only very limited data exist to inform BP thresholds for widely used 
bleeding risk scores in people being prescribed DOACs in the real world setting.  
Nonetheless, international guidelines on secondary prevention post-stroke advocate assessment 
of patients using bleeding risk scores when considering anticoagulation for atrial fibrillation 
[8]. Hypertension is included as a modifiable risk factor across the three widely accepted 
bleeding risk scores [9-11]. Importantly a threshold of 160mmHg systolic BP is provided as a 
guide for uncontrolled hypertension within these scoring matrices but optimal levels on 
treatment are not given and trial data that might inform are unavailable [9-11].  
In addition, the National Institute for Health and Care Excellence (NICE) in the United 
Kingdom, advises assessment of stroke risk using the CHA2DS2-VASc score; anticoagulation 
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being offered to those with a CHA2DS2-VASc ≥2 or above with consideration for bleeding risk 
[12]. Overall, there is a paucity of evidence as to ideal BP levels when patients are on 
anticoagulant therapy and if higher levels within the normal range are associated with reduced 
hemorrhage risk.  Therefore, we sought to investigate the incidence rate for the combined 
primary outcome of a diagnosis of first stroke, recurrent stroke, myocardial infarction, 
symptomatic intracranial bleed or significant gastrointestinal bleed by post-initiation BP for 
patients with AF commenced on DOACs therapy, using real world data. 
MATERIALS AND METHODS 
Study design and data source 
This observational retrospective cohort study included a sample of primary care patients in 
England who were registered with practices contributing to the Clinical Practice Research 
Datalink (CPRD). The CPRD includes anonymised primary care electronic health records for 
over 11.3 million patients from 674 UK practices dating back to 1987 [13]. The CPRD includes 
data on approximately 6.9% of the UK population [13]. The data are broadly representative of 
the age, sex and ethnicity of the UK general population [13].  
The study included all patients with a diagnosis of AF registered at practices contributing to 
the CPRD (Table I in the Supplementary Files). All patients were aged 18 years or older and 
initiated treatment with DOACs (Dabigatran, Apixaban, Rivaroxaban, Edoxaban) from 1 
February, 2010 (earliest record) to 31 December, 2017. The index date was the first BP 
measurement following the first recorded prescription for a DOAC (Table II in the 
Supplementary Files). Patients were only included if linkage to Hospital Episode Statistics 
(HES) Admitted Patient Care database and Office of National Statistics (ONS) for mortality 
were available. Since linkage is only available for England, patients in Scotland and Ireland 
were automatically excluded from the sample. Follow-up began at the index date until the first 
event defined as a diagnosis of stroke, recurrent stroke, myocardial infarction, symptomatic 
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intracranial bleed, significant gastrointestinal bleed, death, or censoring (transferring out of 
practice, last collection of data from practice, or end of study on 31 December, 2017, whichever 
came first). Patients without at least one BP measurement within one year after DOAC 
initiation and whose first post-DOAC initiation BP was taken after experiencing an event were 
excluded. BP measurements that were not within a biologically plausible range (90-210mmHg) 
were excluded. 
Exposure 
Exposure was defined using “post-initiation” systolic BP; that is the systolic BP recorded in 
CPRD, closest to the date of DOACs initiation, and limited to a maximum of 365 days after 
DOACs initiation. Post-initiation BP was treated as a continuous variable for some analyses 
and divided into four clinically relevant groups (90-120, 121-140, 141-160, 161-210) for 
others.  
Outcome  
The primary outcome was the time until the first event after starting DOAC, defined as the first 
recorded diagnosis of stroke, recurrent stroke, myocardial infarction, symptomatic intracranial 
bleed, or significant gastrointestinal bleed occurring during the study period (Table III in the 
Supplementary Files). Diagnoses were obtained from either primary (CPRD) or secondary care 
(Hospital Episode Statistics (HES), first diagnosis position). All-cause mortality and 
cardiovascular-related mortality were investigated as secondary outcomes and were obtained 
from ONS. Cardiovascular mortality was a death with an underlying cause including ischemic 
heart disease (ICD-10 codes I20–I25), cardiac failure (I11, I13, I50), cerebrovascular disease 




Demographic information, age and sex, and current alcohol use were obtained from CPRD. 
Current alcohol use was defined as one or more CPRD records indicating current alcohol use 
within 365 days before the index date. All other patients were considered non-current alcohol 
users. Pre-existing conditions including history of stroke or ischemic heart disease, dementia 
(as a surrogate for presence of small vessel disease), and liver disease were obtained from either 
primary (CPRD) or secondary care (HES, any diagnosis position) and were dated on or before 
the index date (Table IV in the Supplementary Files).   
Statistical analyses 
The incidence rate was calculated for the primary outcome and secondary outcomes by post-
initiation BP. Cox regression modelling was used to investigate the association between post-
initiation BP and the primary and secondary outcomes. Crude and adjusted hazard ratios (HR) 
were calculated for 10mmHg increases in systolic BP. HRs were adjusted for age, sex, current 
alcohol use, and comorbid stroke/ischemic heart disease, dementia, and liver disease. All 
analyses were performed in STATA 15 and SAS v9.4. 
RESULTS 
13,200 patients were initially extracted from the CPRD database, however following 
exclusions due to absence of post initiation BP measurement, index date after 31/12/17, date 
of death before index date and event before index date, 9,051 patients were included in the 
study (Figure 1). Post-DOACs initiation systolic BPs are also shown in Figure 1; these ranging 
from 90mmHg to 210mmHg. The cohort characteristics are well matched across all BP groups 
(Table 1). Within the study cohort, 832 events occurred and 1,013 all-cause deaths of which 
249 were attributed to cardiovascular causes during 14,147 person-years of follow-up (mean 
1.6 years (SD 1.2), maximum 6.9 years). The most common event was GI bleeding (n=285, 
34.3% of events), while the least common was intracerebral hemorrhage (n= 75, 9.0% of 
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events).  The distribution of post-initiation systolic BP in CPRD patients on DOACs is shown 
in Figure I in the Supplementary Files. The 90% of BPs fell between 110-152mmHg. The 
distribution of days between DOACs initiation and post-DOACs initiation systolic BP 
measurements demonstrated highest densities during the first 50 days. The mean number of 
days between initiation and BP measurement was 89.6 (SD 85.7) for patients with BP 90-
120mmHg, 95.9 (SD 87.4) for patients with BP 121-140mmHg, 93.4 (SD 87.4) for patients 
with BP 141-160mmHg, and 87.4 (SD 85.7) for patients with BP 161-210mmHg (Figure II in 
the Supplementary Files). Figure III in the Supplementary Files demonstrates the highest 
density of initiation occurred between 2016-2017 for Apixaban, Edoxaban, and Rivaroxaban. 
On the other hand, the highest density of Dabigatran initiation was between 2013-2014. 
The incidence rate for an event, all-cause, and cardiovascular mortality by post-DOAC 
initiation is shown in Table 2. Patients with BP 161-210mmHg had the highest event rate, 78.8 
(95% CI 61.3-101.3) per 1,000 person-years. Patients with BP 121-140 mmHg had the lowest 
event rate, 55.0 (49.7-60.9) per 1,000 person-years. Patients with BP 90-120 had the highest 
all-cause and cardiovascular mortality rates, 105.3 (95% CI 95.7-115.8) and 23.7 (95% CI 19.4-
29.0) per 1,000 person-years, respectively. On the other hand, patients with BP 161-210mmHg 
had the lowest all-cause mortality rate and patients with BP 121-140 had the lowest 
cardiovascular mortality rate, 50.4 (95% CI 36.8-69.0) and 14.3 (95% CI 11.8-17.5) per 1,000 
person-years, respectively.  
 
First, we confirmed that the relationship between systolic BP and log relative risk of an event 
was linear so splines were not required.  The Cox proportional HR of all-cause mortality (crude 
HR 0.83 [95% CI 0.80-0.86], p=0.000; adjusted HR 0.84 [95% CI 0.81-0.87], p=0.000) and 
cardiovascular mortality (crude HR 0.92 [95% CI 0.85-0.99], p=0.021; adjusted HR 0.93 [95% 
CI 0.86-1.00], p=0.041) demonstrated a significant inverse relationship with each 10mmHg 
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increase in systolic BP. On the other hand, the hazard of an event (crude HR 1.04 [95% CI 
1.00-1.08], p=0.077; adjusted HR 1.04 [95% CI 1.00-1.08], p=0.071) was not significantly 
associated with 10mmHg increases in systolic BP.  We also examined the hazard of a 
significant bleeding event (intracranial hemorrhage and GI bleeding), which did not differ 
significantly with each 10mmHg increase in systolic BP (crude and adjusted HR 1.01 [95% CI 
0.95-1.07], p=0.769 and 0.745, respectively).  
Events 
Adjusted event data with the 140mmHg and 120mmHg reference levels demonstrated a trend 
towards lower BP levels (<90mmHg) being associated with lower event rates as compared to 
systolic BP levels >200mmHg (Figure 2). The 140mmHg level pertains to a threshold 
perceived to describe a clinically important reduction in BP as part of a secondary prevention 
strategy [14]. The 160mmHg reference level demonstrates a similar relationship with systolic 
BP values with 150mmHg demonstrating increased risk of an event and 170mmHg 
demonstrating a trend towards lower risk (Figure 2). The nadir at 120mmHg is noted across all 
BP reference values and associates with a lower event rate (Figure 3).  
All-cause mortality 
All-cause mortality with the 140mmHg and 120mmHg reference levels demonstrated a 
significant linear trend towards higher mortality with lower systolic BP (<120mmHg) and 
lower mortality with higher systolic BP (>140mmHg) (Figure 2). This linear relationship was 
also demonstrated with the 160mmHg reference level (Figure 2).  The nadir is 160mmHg and 
associates with lower all-cause mortality (Figure 3). 
Cardiovascular mortality 
Cardiovascular mortality with the 140mmHg and 120mmHg reference levels demonstrated a 
significant linear trend towards higher cardiovascular mortality with lower systolic BP 
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(<120mmHg) and lower cardiovascular mortality with higher systolic BP (>120mmHg) 
(Figure 2). The nadir is at 130mmHg and associates with a trend towards lower cardiovascular 
mortality (Figure 3). 
Bleeding events 
Bleeding related events demonstrated little variation based on systolic BP change from the 
140mmHg and 160mmHg reference ranges (Figure IV in the Supplementary Files). 
Prior ischemic heart disease or stroke 
Higher systolic BP >160mmHg conferred an all-cause and cardiovascular mortality benefit in 
those with and without prior IHD/stroke disease (Figure V in the Supplementary Files). In 
addition, in those without a history of IHD/stroke there was a significant benefit up to the 
reference point of 140mmHg. This negative linear relationship for systolic BP and all-cause 
and cardiovascular mortality was comparable in those without a history of IHD/stroke. 
However, in those with a history of IHD/stroke, there was a much flatter relationship albeit 
with a paradoxical demonstration of the lowest systolic BP levels of 60mmHg conferring a 




This is the first study to our knowledge to provide data on the relationship between systolic BP 
post-DOAC initiation in patients with AF and clinical outcomes. The main finding of this study 
is that BP values below 161mmHg were associated with higher all-cause mortality risk but 
lower event risk. 
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Low systolic BP (121-140) confers no benefit in minimising events compared to the highest 
BP group (within 161-210mmHg), but confers a significantly greater risk of death (all-cause 
crude and adjusted). Therefore, increasing hypotension (<100mmHg) could be considered a 
prognostic marker of adverse outcomes, possibly driven by cardiac failure as recent work in 
AF patients has shown [15], or overall poor cardiac performance mediated by cardiovascular 
morbidity. The mortality risk is not reflected in patients with systolic BP values between 120-
200mmHg and cardiovascular mortality is not significantly affected by significant 
hypertension (180-200mmHg). 
Hypotension as a marker of poor prognosis 
A terminal decline of systolic BP in the final two years of life has been demonstrated in a large 
registry study [16]. The relative odds of systolic BP <120mmHg were higher in the last 3 
months of life as compared to 5 years previously. With a mean age of 77.2 years across all 
systolic BP quintile groups, it is highly possible that some individuals within this study will be 
on this systolic BP trajectory [16]. Furthermore, previous data support hypotension in patients 
with cardiovascular disease, being at higher risk of further cardiovascular events [17]. In those 
with AF, post hoc analysis of the Atrial Fibrillation Follow-Up Investigation of Rhythm 
Management (AFFIRM) trial demonstrated convergent findings to our study in AF patients on 
Warfarin (i.e. in the pre DOAC era). Similarly, the authors proposed a greater BP target than 
the general population as adverse events were seen if systolic BP was reduced to <110 mmHg 
[19]. In an oral anticoagulant-naïve population, BP of <120/80mmHg was associated with 
higher risk of a major cardiovascular event in patients with AF undergoing hypertension 
treatment [19]. However, recent conflicting findings from the ORBIT-AF registry 
demonstrated higher SBP was associated with increasing adverse events [20]. Our study 
findings are novel as they address BP targets after taking DOAC therapy and assess prognosis 
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in AF patients, providing convergent results to BP data in an anticoagulant naïve AF 
population. 
140mmHg and 120mmHg threshold 
In recent work by Douros and colleagues [21], using 140mmHg as a reference point, systolic 
BP of 125mmHg was associated with significantly increased risk of death, which was not the 
case with higher values of systolic BP (reversed J-shaped curve). This ‘real-world’ study 
highlighted those >80 years of age being particularly susceptible to increased mortality risk 
with BP values <140mmHg. To further support the 140mmHg threshold, analysis of pooled 
data from the Stroke Prevention using an Oral Thrombin Inhibitor in AF III and V trials 
demonstrated those with a mean systolic BP >140mmHg had an increased risk of stroke and 
systemic embolic events [21]. This study supports the findings of this prior work highlighting 
the paradoxical behaviour of event risk and mortality risk around a probable threshold systolic 
BP of 140mmHg [22]. The ‘Bleeding with Antithrombotic Therapy (BAT) study demonstrated 
increasing BP levels positively associate with development of ICH and highlight the 
importance of adequate BP control [23]. This study provided an estimated cut off BP (using 
ROC curve analyses) to predict impending risk of ICH as ≥130/81mmHg [23]. The BAT study 
enrolled a majority of patients solely on antiplatelet therapy, however, 32.4% were receiving 
anticoagulants [23]. This was significantly more than the preceding PROGRESS study 
(Perindopril Protection Against Recurrent Stroke Study), which only included 10% of patients 
on anticoagulants yet still demonstrated a 50% ICH reduction after mean BP lowering of just 
9/4mmHg [24]. The 120mmHg threshold provides a greater understanding of the nadir across 
events, all-cause and cardiovascular mortality. In particular, the lower event rate (120mmHg) 
and lower cardiovascular mortality (130mmHg) at the respective nadirs provides support for 
current guideline-recommended values. 
160mmHg threshold and HAS-BLED 
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Despite the HAS-BLED score demonstrating better discrimination for all-cause mortality, as 
compared to HEMORR2HAGES and ATRIA [25], there remain questions over ensuring 
systolic BP is below the 160mmHg threshold advocated during initiation of DOACs [9]. Prior 
work has shown the HAS-BLED score is not only useful in the assessment of bleeding risk, 
but also shows some predictive value for cardiovascular events and mortality in anticoagulated 
patients with AF [26]. However, the previously assumed close relationship between bleeding 
and mortality end-points in anti-coagulation studies is debatable considering the data presented 
within this study. Bleeding demonstrated a less pronounced relationship with systolic BP as 
compared to event and mortality risk.  
Previous cohort study data have shown tachycardia, lower BMI, history of chronic renal disease 
and malignant disease were all strongly associated with early death after AF diagnosis (<4 
months). Cardiovascular co-morbidities, as well as chronic illness, were important predictors 
for late death (>4 months) [27].  
Patients with hypertension and AF are three to five times more likely to have a stroke or 
thromboembolic event compared with normotensive individuals with AF [28, 29]. 
Interestingly, our data support BP >200mmHg being preferable to BP <120mmHg in those 
without a stroke/IHD history as compared to those with a stroke/IHD history (Figure V in the 
Supplementary Files). The key findings of the analyses of those with and without a prior history 
of stroke/IHD are the lower event rate at the lowest BP values and higher all-cause mortality 
for those with prior stroke/IHD. This paradoxical behaviour is not in keeping with those 
without prior IHD/stroke or indeed the entire cohort studied. This is an interesting finding as 
hypertension is known to increase the risk of recurrent stroke, but extremes of hypotension in 
the context of presumed chronic stroke and IHD were not previously considered to be 
protective. The presence of heart failure in those with stroke/IHD could explain the potential 
benefit of lower BP values on event risk and cardiovascular mortality risk [15]. This 
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corresponds with prior AFFIRM trial data suggesting that using rhythm control for AF with 
SBP >160mmHg has no significant increase in all-cause mortality [18]. Although we do not 
have data to support higher usage of rhythm control medications in those AF patients without 
a prior history of stroke/IHD, this is a potential confounder to explain these findings. In only 
those with a history of stroke, the demonstration that systolic BP levels >180mmHg appear to 
confer a protective effect on mortality with no significant reduction in events demonstrates 
higher proportion of chronic stroke disease patients included. Additionally, although not 
significant, the more convincing positive linear trend relationship between events and higher 
systolic BP in those with stroke demonstrates once more the trade-off between events and 
mortality. However, once more the hypotension and mortality risk is convincing in those with 
and without a history of stroke, suggesting the AFFIRM trial data are also applicable to this 
patient population. The 2016 ESC guideline recommendation (Class IIa, Level B evidence) 
provides the only current guidance on BP management in AF [8]. Importantly, our study 
demonstrates the need for a prospective study of BP control after anticoagulation to both 
strengthen and refine current guideline recommendations.  
Study limitations  
There are several limitations to consider. The large number of exclusions may have biased the 
results. In addition, concerns exist over BP measurement in patients with AF due to limited 
evidence and significant heterogeneity in the studies that validated automated BP monitors in 
AF. Given the observational nature of the study, the methodology for BP measurement was not 
standardised, however BP measurement guidelines exist within the UK [30]. Additionally, 
meta-analyses have shown that these monitors appear to be accurate in measuring systolic, but 
not diastolic, BP. In the context of clinic measured BP, there is potential for a degree of 
measurement error, though this is unquantifiable and likely to exist for all individuals [31]. 
Furthermore, although BP measurement processes within CPRD have the potential to 
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incorporate “white coat effect” and variations in fidelity to international guidelines for BP 
measurement, they represent actual data from a ‘real world’ primary care setting reflecting 
current clinical practice. Association was also based on a BP measure taken at a single time-
point and without acknowledgement for those on existing anti-hypertensive treatment, the 
effect specific BP agents can have or indeed the effect of different DOAC dosages. Therefore, 
the effect of changes in BP over time were not analysed. DOAC initiation was determined 
based on prescriptions recorded in CPRD. There is potential for misclassification as patients 
may not have filled, initiated, or adhered to the medication regimen. There may be additional 
measured or unmeasured factors that were not accounted for within the analysis that could 
confound the association between systolic blood pressure and the primary and secondary 
outcomes.  Further, this study was observational in nature, therefore causality cannot be 
determined. However, there are significant strengths including the large cohort size, multi 
variables available within CPRD and robust analyses and adjustments.  
In conclusion, this study demonstrated that systolic BP values below 161mmHg are associated 
with higher all-cause and cardiovascular mortality risk, but lower event risk in patients with 
AF on DOAC therapy. This demonstrates a need for a prospective interventional study of BP 
control after initiation of anticoagulation. 
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No post-initiation BP measurement 3 171
Index date after 31/12/2017 457
Date of death before index date 3
Event before index date 518




All-cause deaths 1 013
Cardiovascular deaths 249








Figure 2. Adjusted Cox proportional hazard ratios of an event, all-cause mortality, and cardiovascular 






Figure 3. Adjusted Cox proportional hazard ratios (restricted cubic splines) of an event, all-cause 
mortality, and cardiovascular mortality in CPRD patients on DOACs (reference 160mmHg, 140mmHg 
and 120mmHg).  
Adjusted for sex, age, stroke/ischemic heart disease, dementia, liver disease, and current alcohol use. 
Events include first stroke, recurrent stroke, myocardial infarction, symptomatic intracranial bleed, 





Table 1. Cohort characteristics by post-DOACs initiation systolic blood pressure groups in CPRD 
patients on DOACs. 
  
Post-initiation systolic blood pressure (mmHg) 
Total 90-120 121-140 141-160 161-210 
Total N=2,720 N=4,191 N=1,651 N=489 N=9,051 
Sex      
 Male 1,540 (56.6%) 2,245 (53.6%) 858 (52.0%) 210 (42.9%) 4,853 (53.6%) 
 Female 1,180 (43.4%) 1,946 (46.4%) 793 (48.0%) 279 (57.1%) 4,198 (46.4%) 
DOACs Initiated      
Apixaban 853 (31.4%) 1,278 (30.5%) 526 (31.9%) 165 (33.7%) 2,822 (31.2%) 
Dabigatran 414 (15.2%) 709 (16.9%) 262 (15.9%) 87 (17.8%) 1,472 (16.3%) 
Edoxaban 17 (0.6%) 29 (0.7%) 8 (0.5%) 0 (0.0%) 54 (0.6%) 
Rivaroxaban 1,436 (52.8%) 2,175 (51.9%) 855 (51.8%) 237 (48.5%) 4,703 (52.0%) 
Medical history      
Stroke/IHD 1,241 (45.6%) 1,775 (42.4%) 692 (41.9%) 216 (44.2%) 3,924 (43.4%) 
Dementia 320 (11.8%) 327 (7.8%) 109 (6.6%) 32 (6.5%) 788 (8.7%) 
Liver disease 74 (2.7%) 85 (2.0%) 33 (2.0%) 11 (2.2%) 203 (2.2%) 
Current alcohol use* 590 (21.7%) 942 (22.5%) 348 (21.1%) 99 (20.2%) 1,979 (21.9%) 
Age 77.2 (11.1) 76.9 (10.5) 77.5 (10.3) 78.6 (9.3) 77.2 (10.6) 
AF duration (years) 4.3 (5.5) 4.5 (5.6) 4.4 (5.4) 4.7 (5.7) 4.4 (5.5) 
Post-initiation BP time 
(days) 89.6 (85.7) 95.9 (87.4) 93.4 (87.4) 87.4 (85.7) 93.1 (86.8) 
IHD=ischemic heart disease. 
Age, AF duration, and post-initiation BP time are shown as mean (standard deviation). 
AF duration (years)=years between first atrial fibrillation diagnosis and post-initiation BP measurement. 
Post-initiation BP time (days)=days between DOACs initiation and post-initiation BP measurement. 












Table 2. Incidence rate for an event, and all-cause and cardiovascular mortality by post-DOAC 








n Rate (95% CI) n Rate (95% CI) n Rate (95% CI) 
90-120 4,007 227 56.6 (49.7-64.5) 422 105.3 (95.7-115.8) 95 23.7 (19.4-29.0) 
121-140 6,763 372 55.0 (49.7-60.9) 409 60.5 (54.9-66.6) 97 14.3 (11.8-17.5) 
141-160 2,604 172 66.1 (56.9-76.7) 143 54.9 (46.6-64.7) 44 16.9 (12.6-22.7) 
161-210 774 61 78.8 (61.3-101.3) 39 50.4 (36.8-69.0) 13 16.8 (9.8-28.9) 
Total 14,147 832 58.8 (54.9-62.9) 1,013 71.6 (67.3-76.2) 249 17.6 (15.5-19.9) 
Rate=per 1,000 person-years 
